Cannabinoids Clinical Trials Data Terpenes 
The Cannigma
JANUARY 13, 2023
Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. The study called out pinene, myrcene, and beta-caryophyllene as specifically useful terpenes.
Project CBD
MAY 3, 2023
Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JULY 1, 2022
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.
The Joint Blog
FEBRUARY 18, 2020
According to NORML, they reported that the use of medical cannabis, and in particular products dominant in the cannabinoid CBN (cannabinol), was associated with medication-sparing effects. The study is titled Cannabinoid and terpenoid doses are associated with adult ADHD status of medical cannabis patients.
Veriheal
APRIL 11, 2022
We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. We could potentially develop north of 11,000 drugs that are cannabinoid-based. This means that U.S.
The Joint Blog
JANUARY 23, 2020
.” For this study, “The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted.” One isolated study indicates some potential efficacy for an oral cannabinoid /terpene combination in ADHD.
NORML
SEPTEMBER 20, 2019
Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials. The testing did confirm that the [batch sent by NIDA] has cannabinoids, some very minute quantities of terpenes in it, and that it was cannabis.
Expert insights. Personalized for you.
132 
Let's personalize your content